TALIAZ LTD

Their core work

Taliaz is an Israeli healthtech SME that built Predictix, an AI-powered clinical decision support tool for psychiatrists treating depression. Their core product analyses a patient's genomic profile alongside clinical and demographic data to predict which antidepressant is most likely to work — reducing the trial-and-error cycle that leaves many patients undertreated for months. They went from a feasibility prototype to a fully funded commercial product through the EU SME Instrument, executing both phases entirely as sole coordinator. Their work sits at the intersection of pharmacogenomics, clinical AI, and mental health — a niche but high-value space with clear diagnostic and commercial relevance.

What they specialise in

How they've shifted over time

Taliaz has followed a tight, focused trajectory with essentially no pivot: they entered H2020 with a proof-of-concept for genomic-based antidepressant selection and exited with a scaled commercial product. The Phase 1 project (2018–2019) carried no keywords in the CORDIS record, reflecting its early-stage exploratory character. By the Phase 2 project (2020–2023), the keyword set crystallised around depression, predictive analysis, antidepressants, AI, and machine learning — indicating the technology stack had matured and the team had a clear, articulated value proposition. There is no evidence of scope broadening or sectoral diversification; their evolution is one of deepening, not widening.

Taliaz is a product company, not a research lab — their H2020 trajectory points toward commercialisation and market entry rather than further foundational R&D, making them a more interesting acquisition or licensing target than a consortium research partner.

How they like to work

Taliaz consistently led both their H2020 projects as sole coordinator, with no registered consortium partners in the CORDIS data — a pattern typical of SME Instrument grants, which are designed for single-company product development rather than multi-partner research. This means they operate independently and are not experienced in large consortium dynamics. Anyone seeking a collaboration with Taliaz should approach them as a technology provider or commercial partner, not as a co-investigator in a traditional research project.

Taliaz has no registered consortium partners across their two H2020 projects, which is expected for SME Instrument grants. Their external network is likely built through clinical validation partners, hospital contacts, and psychiatric research groups — but these relationships are not visible in the CORDIS data.

What sets them apart

Taliaz occupies a narrow but defensible niche: AI-guided antidepressant selection backed by EU-validated R&D funding, developed by an Israeli SME with access to both European and Middle Eastern clinical markets. Unlike generic clinical AI companies, their focus on a single therapeutic area (depression) and a single decision point (which antidepressant to prescribe) makes their product immediately actionable for psychiatrists. For anyone building a consortium around precision psychiatry, digital mental health, or pharmacogenomics tools, Taliaz brings a proven technology with real EU funding history behind it.

Highlights from their portfolio

• Predictix
  The Phase 2 SME Instrument grant of EUR 2.48M is the largest single award in their portfolio and confirms EU assessors validated both the technology and the commercial case for AI-driven antidepressant selection at scale.
• Predictix Antidepres
  The Phase 1 feasibility grant (EUR 50K, 2018–2019) is notable as the proof-of-concept that unlocked the much larger Phase 2, demonstrating a clean and successful SME Instrument two-phase trajectory.